Curated Optogenetic Publication Database

Search precisely and efficiently by using the advantage of the hand-assigned publication tags that allow you to search for papers involving a specific trait, e.g. a particular optogenetic switch or a host organism.

Showing 1 - 1 of 1 results
1.

PIP2 regulation of TRPC5 channel activation and desensitization.

blue CRY2/CIB1 HEK293T Immediate control of second messengers
J Biol Chem, 29 Apr 2021 DOI: 10.1016/j.jbc.2021.100726 Link to full text
Abstract: Transient receptor potential canonical type 5 (TRPC5) ion channels are expressed in the brain and kidney, and have been identified as promising therapeutic targets whose selective inhibition can protect against diseases driven by a leaky kidney filter, such as Focal Segmental Glomerular Sclerosis (FSGS). TRPC5 channels are activated by elevated levels of extracellular Ca2+or lanthanide ions, but also by G protein (Gq/11) stimulation. Phosphatidylinositol bisphosphate (PIP2) hydrolysis by phospholipase C (PLC) enzymes leads to protein kinase C (PKC)-mediated phosphorylation of TRPC5 channels and their subsequent desensitization. However, the roles of PIP2 in activation and maintenance of TRPC5 channel activity via its hydrolysis product diacyl glycerol (DAG), as well as the mechanism of desensitization of TRPC5 activity by DAG-stimulated PKC activity remain unclear. Here, we designed experiments to distinguish between the processes underlying channel activation and inhibition. Using whole-cell patch clamp, we employed an optogenetic tool to dephosphorylate PIP2 and assess channel-PIP2 interactions influenced by activators, such as DAG, or inhibitors, such as PKC phosphorylation. Using total internal reflection microscopy, we assessed channel cell surface density. We show that PIP2 controls both the PKC-mediated inhibition as well as the DAG- and lanthanide-mediated activation of TRPC5 currents via control of gating rather than channel cell surface density. These mechanistic insights promise to aid in the development of more selective and precise inhibitors to block TRPC5 channel activity, and to illuminate new opportunities for targeted therapies for a group of chronic kidney diseases for which there is currently a great unmet need.
Submit a new publication to our database